Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 7/20 | 0.51 |
| ▸ | RARG | P13631 | 7/20 | 0.51 |
| ▸ | RARA | P10276 | 5/20 | 0.51 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 10/20 | 0.42 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.39 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6574370 | 0.89 | RARB (0.67) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL8616759 | 0.87 | RARB (0.42) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL6578033 | 0.86 | RARA (0.40) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL8614817 | 0.83 | RARB (0.52) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL6578025 | 0.80 | RARB (0.65) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL6574407 | 0.79 | HSD11B1 (0.42) | RARBRARGRARACYP3A4 | |
| SCHEMBL6575676 | 0.76 | RARB (0.39) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL6574397 | 0.75 | RARA (0.37) | RARBRARGRARA | |
| SCHEMBL20061936 | 0.74 | HSD11B1 (0.38) | RARBRARGCYP3A4 | |
| SCHEMBL6576434 | 0.74 | RARB (0.48) | RARBRARGRARACYP26A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0937045-B1 | N-ARYL SUBSTITUTED TETRAHYDROQUINOLINES LIGANDS FOR RETINOID RECEPTORS HAVING AGONIST, ANTAGONIST OR INVERSE AGONIST TYPE ACTIVITY | ALLERGAN INC (US) | 2004-04-28 | — | — | EP | disclosed |